Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary 2013 Annual Report & Proxy
2013 Annual Report & Proxy
View HTML
Toggle Summary Appendix 3Y - Change of Director's Interest Notice View HTML
Toggle Summary Appendix 3Y - Change of Director's Interest Notice View HTML
Toggle Summary Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms
CAS Group Supports Improved Deal Company Currently has Sufficient Votes to Approve Merger ATLANTA , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that the reconvened Special Meeting of Stockholders has been further adjourned to 10:00 AM, EST on February
View HTML
Toggle Summary Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018
Board of Directors Unanimously Recommends that Aviragen Stockholders Vote FOR the Vaxart Merger
View HTML
Toggle Summary Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders
Aviragen Stockholders to Own 49% of Combined Company, Up from 40% Under the Previous Agreement
View HTML
Toggle Summary Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart
Transaction Creates a Leading Vaccine Company and Maximizes Value for Aviragen Stockholders Updated Investor Presentation Filed with Securities and Exchange Commission and Posted to Aviragen Website ATLANTA , Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
View HTML
Toggle Summary Aviragen Comments on ISS Report
Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote FOR the Proposed Merger with Vaxart ATLANTA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aviragen
View HTML
Toggle Summary Aviragen Provides New Information Supporting Vote FOR Vaxart Merger
Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders CAS Group Has Not Articulated a Clear Plan and Has Now Changed its Stance to Emphasize Teslexivir (BTA074) ATLANTA , Jan. 31, 2018 (GLOBE NEWSWIRE) --   Aviragen Therapeutics, Inc.
View HTML
Toggle Summary Aviragen Therapeutics and Vaxart Enter into Merger Agreement View HTML

Log In

Create an account